Qualified Clinical Outcome Assessments (COA)
The table below lists qualified Clinical Outcome Assessments (COA). The tables include legacy projects (those submitted prior to passage of the 21st Century Cures Act), as well as those submitted as part of the newer section 507 process (referring to section 507 of the Federal Food, Drug and Cosmetic Act (FD&C Act)), which was created by Section 3011 of the 21st Century Cures Act). The tables are updated on a biannual basis and provide information on the COA qualification project, qualification statement, and supporting information. Additionally, the table includes documents from requestors that were received after the passage of the 21st Century Cures Act.
FDA’s posting of information submitted to the agency by outside parties requesting qualification of a drug development tool is not an endorsement or recommendation by FDA. Information about submissions are made publicly available in accordance with section 507 of the FD&C Act. FDA makes no representations, guarantees, or warranties as to the accuracy, completeness, currency, or suitability of the information about submissions. See the FDA decision letter corresponding to each submission for FDA considerations and recommendations related to each request for qualification.
To view information about submissions to the CDER COA Qualification Program for which final COA qualification determinations have not yet been made, please visit: Clinical Outcome Assessments (COA) Qualification Submissions.
Office of Cardiology, Hematology, Endocrinology, and Nephrology (OCHEN)
Division of Cardiology and Nephrology (DCN)
| Disease/Condition | DDT COA Number and Instrument Name | Concept of Interest | Context of Use | COA Type |
|---|---|---|---|---|
| Chronic Heart Failure (CHF) | DDT COA #000084: Kansas City Cardiomyopathy Questionnaire (KCCQ) | CHF symptoms and their impact on physical limitations | Patients with CHF | PRO |
Office of Neuroscience (ON)
Division of Psychiatry (DP)
| Disease/Condition | DDT COA Number and Instrument Name | Concept of Interest | Context of Use | COA Type |
|---|---|---|---|---|
| Major Depressive Disorder (MDD) | DDT COA #000008: Symptoms of Major Depressive Disorder Scale (SMDDS) | Overall symptoms of MDD | Adults (>18 years) with a clinical diagnosis of MDD and:
| PRO |
Office of Immunology and Inflammation (OII)
Division of Gastroenterology (DG)
| Disease/Condition | DDT COA Number and Instrument Name | Concept of Interest | Context of Use | COA Type |
|---|---|---|---|---|
| Irritable Bowel Syndrome (IBS) | DDT COA #000005: Diary for Irritable Bowel Syndrome Symptoms- Constipation (DIBSS-C) | Aspects of symptom experience associated with irritable bowel syndrome with constipation | Patients 18 years and older with a diagnosis of IBS-C as defined by the Rome Criteria and the final FDA IBS Guidance | PRO |
Division of Pulmonary, Allergy, and Critical Care (DPACC)
| Disease/Condition | DDT COA Number and Instrument Name | Concept of Interest | Context of Use | COA Type |
|---|---|---|---|---|
| Asthma | DDT COA #000006: Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD) | Asthma symptoms | Adolescent (12 -17 years) and adult patients | PRO |
| Chronic Obstructive Pulmonary Disease (COPD) | DDT COA #000017: Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS: COPD) | Respiratory symptoms of stable COPD | Adult outpatients with stable COPD | PRO |
Office of Infectious Diseases (OID)
Division of Anti-Infectives (DAI)
| Disease/Condition | DDT COA Number and Instrument Name | Concept of Interest | Context of Use | COA Type |
|---|---|---|---|---|
| Acute Bacterial Exacerbation of Chronic Bronchitis in patients with Chronic Obstructive Pulmonary Disease (ABECB-COPD) | DDT COA #000003: Exacerbations of Chronic Pulmonary Disease Tool (EXACT) | Symptoms of ABECB-COPD | Outpatients with ABECB-COPD who meet the clinical trial entry criteria as described in the FDA Guidance: Acute Bacterial Exacerbations of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease: Developing Antimicrobial Drugs for Treatment. | PRO |
Office of Oncologic Diseases (OOD):
Division of Oncology 2 (DO 2)
| Disease/Condition | DDT COA Number and Instrument Name | Concept of Interest | Context of Use | COA Type |
|---|---|---|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | DDT COA #000009: Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) | Symptom severity (cough, pain, dyspnea, fatigue, and appetite) | Adult patients (> 18 years) with Stage IIIB or IV NSCLC that are:
| PRO |
Resources for You